Try our Advanced Search for more refined results

April 28, 2021

CELGENE CORPORATION v. HIKMA PHARMACEUTICALS USA, INC.

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. April 29, 2021

    Celgene Sues Hikma To Block Revlimid Generic

    Celgene has hit Hikma Pharmaceuticals USA Inc. with a lawsuit in New Jersey federal court seeking to block Hikma from marketing generic versions of the Bristol-Myers Squibb unit's cancer drug Revlimid.

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login